Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of balinatunfib in adult Crohn's disease and ulcerative colitis patients
CTR20261151Phase 2Active
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of balinatunfib in Crohn's disease, autoimmune colitis, sponsored by Sanofi. Started Apr 2026; status: active.
02
Drugs
balinatunfib
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on CTR20261151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261151.